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background:  Symptomatic atrial fibrillation (AF) is thought to occur in at least 20% of patients with hypertrophic cardiomyopathy 
(HCM), however, the burden and clinical significance created by asymptomatic and “silent” AF in HCM is unknown. Asymptomatic AF is 
often detected at routine device follow-up, and indications for rhythm-control strategies and anticoagulation are not well-defined for this 
population.
Methods:  To this purpose, we studied 288 consecutive HCM patients implanted with implantable cardioverter-defibrillators (ICD). 
Intracardiac electrocardiograms (EGMs) were reviewed to document presence of AF. We compared the baseline characteristics and rates 
of stroke between patients with known and occult AF (Table).
results:  Occult asymptomatic AF was documented in 27/288 (9%) patients. Of the 27 patients, 2 had embolic strokes (without 
anticoagulation), and 6 (22%) developed paroxysmal symptomatic episodes of AF over the course of 12.1 ± 5.9 months.
Conclusion:  In a large HCM cohort, we identified nearly 10% of patients with occult episodes of AF through routine device interrogation. 
These patients were at risk for embolic events and/or developed paroxysmal symptomatic AF. These findings form the basis for additional 
studies evaluating stroke risk and progression to symptomatic AF in this cohort, and consideration for more aggressive surveillance, earlier 
anticoagulation, and anticipation of targeted rhythm-control strategies.
 
